These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [A phase I trial of idarubicin by oral administration].
    Author: Ogawa M, Kimura K, Taguchi T, Wakui A, Hattori M, Shimoyama T, Fujita H.
    Journal: Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 1):1896-900. PubMed ID: 3473981.
    Abstract:
    A phase I trial of a new anthracycline derivative, idarubicin, was conducted in 16 patients with various advanced solid tumors. Doses administered were 20, 30 and 40 mg/m2 with single oral doses. Dose-limiting factors were both leukopenia and thrombocytopenia reaching a nadir about 2 weeks after the start of treatment and requiring 7 to 10 days for recovery. Other toxicities were anorexia, nausea and vomiting, but alopecia did not occur. The maximum tolerated dose was judged to be 40 mg/m2 and the recommended dose for phase II trials was determined to be 30-35 mg/m2.
    [Abstract] [Full Text] [Related] [New Search]